Riskpilot← Back to searchSign inGet full accessC4PAIN ApS
APSActiveCVR 32292402M.A. Schultz Vej 7Research and experimental development on natural sciences and engineering · NACE 7210Est. 2009— employees
Revenue 2025
DKK 159K
-87% vs 2024
EBITDA margin
100.0%
-87% vs 2024
Equity ratio
95.4%
Financial strength
Net profit 2025
DKK 186K
-83% vs 2024
| Revenue | DKK 159K | -87% |
| EBITDA | DKK 159K | -87% |
| Net profit | DKK 186K | -83% |
| Total assets | DKK 4,4M | -1% |
| Equity | DKK 4,2M | +5% |
| Employees | — | — |
Legal name
C4PAIN ApS
CVR number
32292402
Legal form
Anpartsselskab
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
21. juli 2009
Share capital
DKK 75.000
Employees
—
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af direktionen.
Company purpose
Selskabets formål er at etablere og udføre visse forskningsaktiviteter for selskabets medicinal- og biotekklienter samt forskning, in-licensering og klinisk udvikling af compounds til smertebehandling.
Address
M.A. Schultz Vej 7
Phone
+4520940764
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.115 | -448 | 285 | -405 | -453 | 666 | 1.765 | 474 | 658 | 53 | 252 | 28 | 1.257 | 159 |
| Staff expenses | -125 | -98 | -38 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | 1.990 | -546 | 247 | -405 | -453 | 666 | 1.765 | 474 | 658 | 53 | 252 | 28 | 1.257 | 159 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -7 | -7 | -8 | -8 | -8 | -1 | -1 | -0 | -0 |
| EBIT | 1.990 | -546 | 247 | -405 | -453 | 659 | 1.758 | 466 | 650 | 45 | 251 | 26 | 1.257 | 159 |
| Net financials | 46 | 141 | -7 | -4 | -1 | 10 | 46 | 47 | 46 | 48 | 54 | 99 | 121 | 81 |
| Profit before tax | 2.036 | -405 | 241 | -409 | -454 | 669 | 1.804 | 513 | 697 | 93 | 305 | 125 | 1.378 | 241 |
| Tax | 2.422 | -2.001 | -0 | -174 | -80 | 10 | 398 | 113 | 155 | 23 | 68 | 28 | 304 | 55 |
| Net profit | -386 | 1.596 | 241 | -235 | -374 | 660 | 1.406 | 400 | 542 | 70 | 237 | 97 | 1.075 | 186 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 8.493 | 2.838 | 1.350 | 559 | 1.533 | 820 | 2.023 | 2.158 | 2.760 | 2.601 | 2.927 | 2.975 | 4.405 | 4.366 |
| Equity | 2.658 | 520 | 761 | 526 | 152 | 812 | 1.559 | 1.958 | 2.500 | 2.570 | 2.808 | 2.904 | 3.979 | 4.165 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 3.934 | 2.318 | 589 | 33 | 1.381 | 8 | 465 | 199 | 260 | 31 | 119 | 71 | 426 | 201 |
| Total debt | 3.934 | 2.318 | 589 | 33 | 1.381 | 8 | 465 | 199 | 260 | 31 | 119 | 71 | 426 | 201 |
EBITDA margin
100.0%
This company
15.8%
Market median
+533% vs market
20122025
Equity ratio
95.4%
This company
38.2%
Market median
+150% vs market
20122025
Return on equity
4.5%
This company
18.4%
Market median
-76% vs market
20122025
Net profit margin
116.7%
This company
8.1%
Market median
+1341% vs market
20122025
Asset turnover
0.04×
This company
1.12×
Market median
-96% vs market
20122025
Debt / equity
0.05×
This company
0.62×
Market median
+92% vs market
20122025
- Annual report 2025Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
LA Chief Executive Officer | Chief Executive Officer | 2016 | — | — |
HB Founder | Founder | 2009 | — | — |
HC Chief Executive Officer | Chief Executive Officer | 2009 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2009 | — | — | |
| Board of Directors | 2009 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
BIO-MEDICAL CONSULT HOLDING ApS | Company | 100.0% | 100.0% | 2019 |
ANESIDORA AALBORG ApS | Company | 100.0% | 100.0% | 2015 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
BIO-MEDICAL CONSULT HOLDING ApS
C4PAIN ApS Board members of C4PAIN ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lars Arendt-Nielsen | Chief Executive Officer | 0 companies |
| Henrik Bernt Sanders | Founder | 0 companies |
| Hans Christian Hoeck | Chief Executive Officer | 0 companies |
| Claus Henrik Christiansen | Chairman | 0 companies |
| Charles-Hervé Girsault | Board of Directors | 0 companies |